Drug
Csl511 Fibrinogen Concentrate
Csl511 Fibrinogen Concentrate: highest development phase Phase 3, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| CSL511 Fibrinogen concentrate (human) NCT06617897 | Phase 3 | Acquired Fibrinogen Deficiency |
Latest
No recent events.
Follow Csl511 Fibrinogen Concentrate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.